对已知突变 (等离子体和XII因子) 的患者进行临床评估,重点是预防性治疗
Robin Lochbaum1, Susanne Trainotti2, Thomas K Hoffmann1
1Department of Otorhinolaryngology, Head and Neck Surgery, Ulm University Medical Center, Ulm, Germany.
The Journal of dermatological treatment
|December 12, 2023
概括
具有正常C1抑制剂 (HAE-nC1-INH) 的遗传性血管炎患者在使用兰阿德鲁马布预防时表现出改善的症状. 这种治疗通常用于其他HAE类型,为HAE-nC1-INH.提供了一个新的治疗途径.
科学领域:
- 罕见的遗传疾病是罕见的遗传疾病.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 具有正常C1抑制剂 (HAE-nC1-INH) 的遗传性血管炎是一种罕见的遗传性疾病.
- 症状模仿其他遗传性血管 (HAE) 类型,但实验室值正常.
- 关于HAE-nC1-INH治疗的知识有限,大多数药物已被批准用于其他HAE形式.
研究的目的:
- 评估HAE-nC1-INH.的治疗策略.
- 评估lanadelumab在HAE-nC1-INH患者的预防疗法的有效性.
主要方法:
- 在德国治疗中心对HAE-nC1-INH患者的分析.
- 包括已确认HAE-nC1-INH突变的患者.
- 通过验证的问卷来监测疾病的影响.
主要成果:
- 包括18名患有XII因子或等离子素突变的患者.
- 伊卡蒂班特显示了有效的按需治疗反应.
- 拉纳德鲁马布预防导致严重受影响患者的症状和临床过程显著改善.
结论:
- 这项研究为lanadelumab对HAE-nC1-INH的疗效提供了早期的见解.
- 用lanadelumab进行预防治疗是HAE-nC1-INH的可行选择.
- 对HAE-1和HAE-2的治疗策略可以为HAE-nC1-INH的管理提供信息.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
708
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
708
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
526
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
526
Clot Retraction and Fibrinolysis
6.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.1K


